Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 2/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30028274 | 1.00 | HTR7 (0.42) | HTR7RXRAGRIN1GRIN2BCDK9 | |
| SCHEMBL24958754 | 0.90 | HTR7 (0.40) | HTR7GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL30028670 | 0.90 | HTR7 (0.40) | HTR7GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL24956377 | 0.79 | RXRA (0.30) | RXRAGRIN1GRIN2B | |
| SCHEMBL24958950 | 0.77 | TRPM5 (0.45) | HTR7CDK9DYRK1ADYRK2 | |
| SCHEMBL30029030 | 0.77 | TRPM5 (0.45) | HTR7CDK9DYRK1ADYRK2 | |
| SCHEMBL24956474 | 0.76 | HTR7 (0.40) | HTR7 | |
| SCHEMBL24959231 | 0.74 | HTR7 (0.40) | HTR7RXRAGRIN1GRIN2BGABRA1 | |
| SCHEMBL24958881 | 0.74 | HTR7 (0.40) | HTR7 | |
| SCHEMBL30031323 | 0.73 | HTR7 (0.43) | HTR7RXRAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858918-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858918-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| CN-117295729-A | Carboxy-benzimidazole GLP-1R modulating compounds | 吉利德科学公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-117279905-A | Carboxy-benzimidazole GLP-1R modulating compounds | 吉利德科学公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | HTR7 280/4885RXRA 1072/4885GRIN1 1159/4885 |
| US-11858918-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | HTR7 280/4885RXRA 1072/4885GRIN1 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.